# Daclizumab to Treat HIV-Infected Patients

> **NCT00080431** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 10 (—)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Daclizumab

## Key facts

- **NCT ID:** NCT00080431
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03-26
- **Primary completion:** —
- **Final completion:** 2007-12-28
- **Target enrollment:** 10 (—)
- **Last updated:** 2017-07-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00080431

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00080431, "Daclizumab to Treat HIV-Infected Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00080431. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*